Loading organizations...
§ Private Profile · New York City, NY, USA
Clinical-stage biotechnology company focused on preventing and treating whooping cough with next-generation pertussis vaccines.
ILiAD Biotechnologies is a clinical-stage biotechnology company based in Weston, Florida, focused on preventing and treating diseases caused by Bordetella pertussis, the bacterium responsible for whooping cough. The company has secured over $110 million in investment funding and €10 million in European Union grants, advancing its lead candidate, BPZE1, a next-generation pertussis vaccine that has completed four Phase 2 clinical trials. Pertussis causes an estimated 24 million global cases and 160,000 deaths annually. ILiAD licensed BPZE1 from Institut Pasteur de Lille and INSERM in 2013, conducting clinical studies at Vanderbilt University and Karolinska University Hospital. Its subsidiary, BioLyo Technologies, provides contract development and manufacturing for live bacterial products. The company was founded in 2012. Its business model centers on privately held, funded through over $110 million in investment funding and €10 million in European Union grants for R&D, clinical trials, and operations.
ILiAD Biotechnologies has raised $286.6M across 5 funding rounds.
ILiAD Biotechnologies is dedicated to the prevention and treatment of diseases caused by Bordetella Pertussis, the bacterium responsible for whooping cough.
The company utilizes a proprietary B-Tech vector platform to develop its next-generation vaccine candidates for infectious diseases.
ILiAD Biotechnologies is dedicated to the prevention and treatment of diseases caused by Bordetella Pertussis, the bacterium responsible for whooping cough.
The company utilizes a proprietary B-Tech vector platform to develop its next-generation vaccine candidates for infectious diseases.
ILiAD Biotechnologies has raised $286.6M across 5 funding rounds. Most recently, it raised $115.0M Series B in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 10, 2026 | $115M Series B | RA Capital Management | AI Life Sciences, BNP Capital, Janus Henderson Investors | Announced |
| Feb 10, 2026 | $115M Series D | RA Capital Management | AI Life Sciences Investments LLC, BNP Paribas Asset Management, Janus Henderson Investors, BNP Capital | Announced |
| Sep 6, 2022 | $42.8M Series D | Knott Partners | — | Announced |
| Apr 26, 2022 | $1M Grant | National Institute OF Allergy And Infectious Diseases | — | Announced |
| Dec 19, 2018 | $12.8M Series C | Corey Horowitz, SDS Capital Partners | — | Announced |
The company utilizes its proprietary B-Tech vector platform as a core component of its vaccine development strategy. This platform is designed to facilitate the creation of advanced vaccine candidates aimed at eradicating infectious diseases and improving public health outcomes. The focus on pertussis reflects a commitment to tackling a specific and persistent health challenge.
As a clinical-stage entity, ILiAD Biotechnologies is progressing its vaccine candidates through the necessary development phases. The company's work is centered on bringing effective new solutions to market for the prevention and treatment of pertussis, a disease that continues to pose a significant health threat globally.
ILiAD Biotechnologies was founded by Keith Rubin, M.D., who also serves as its Chief Executive Officer. Dr. Rubin is a member of the Executive Board, guiding the company's strategic direction and its efforts in vaccine innovation.